AEON Biopharma, Inc. SEC filings AEON
AEON Biopharma, Inc. has 361 filings in SEC EDGAR's recent list, going back to Dec 23, 2020. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Nov 3, 2026 | — |
| 8-K |
Current report
Material agreement
|
Nov 3, 2026 | Nov 2, 2026 |
| DEF 14A | Proxy statement | Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 23, 2026 | Oct 23, 2026 |
| PRE 14A | Preliminary proxy statement | Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 21, 2026 | — |
| 4 | Insider transaction | Aug 21, 2026 | Aug 19, 2026 |
| 3 | Initial insider ownership | Aug 21, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Other events
|
Jul 23, 2026 | Jul 23, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 21, 2026 | — |
| 8-K |
Current report
Material agreement, Other events
|
Jul 15, 2026 | Jul 13, 2026 |
| 424B4 | Prospectus | Jul 15, 2026 | — |
| EFFECT | Filing | Jul 13, 2026 | — |
| S-1MEF | Filing | Jul 13, 2026 | — |
| S-1/A | Amended registration statement | Jul 9, 2026 | — |
| S-1 | Registration statement | Jul 8, 2026 | — |
| 4 | Insider transaction | Jun 22, 2026 | Jun 17, 2026 |
| 4 | Insider transaction | Jun 22, 2026 | Jun 17, 2026 |
| 4 | Insider transaction | Jun 22, 2026 | Jun 17, 2026 |
| 4 | Insider transaction | Jun 22, 2026 | Jun 17, 2026 |
| 4 | Insider transaction | Jun 22, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 17, 2026 |
| DRS | Filing | May 29, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
| ARS | Annual report to shareholders | Apr 29, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2026 | — |
| DEF 14A | Proxy statement | Apr 29, 2026 | Apr 29, 2026 |
| 4 | Insider transaction | Apr 3, 2026 | Apr 2, 2026 |
| 3 | Initial insider ownership | Apr 3, 2026 | Apr 1, 2026 |
| 8-K |
Current report
Listing notice
|
Apr 3, 2026 | Mar 31, 2026 |
| S-8 | Employee stock plan registration | Mar 31, 2026 | — |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 30, 2026 | Mar 30, 2026 |
| 4 | Insider transaction | Mar 11, 2026 | Feb 17, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 9, 2026 | Mar 6, 2026 |
| 4 | Insider transaction | Mar 5, 2026 | Feb 17, 2026 |
| 4 | Insider transaction | Mar 5, 2026 | Feb 17, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 17, 2026 |
| 424B3 | Prospectus | Feb 18, 2026 | — |
| EFFECT | Filing | Feb 17, 2026 | — |
| CORRESP | Letter to the SEC | Feb 12, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 12, 2026 | — |
| S-3 | Shelf registration | Feb 9, 2026 | — |
| 3 | Initial insider ownership | Jan 29, 2026 | Jan 21, 2026 |
| SCHEDULE 13D | Ownership over 5% (active) | Jan 29, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 29, 2026 | — |
| 8-K |
Current report
Unregistered share sale, Officer or director change, Shareholder vote results, Regulation FD disclosure, Other events
|
Jan 21, 2026 | Jan 21, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| DEF 14A | Proxy statement | Dec 29, 2025 | Dec 29, 2025 |
| PRE 14A | Preliminary proxy statement | Dec 19, 2025 | Dec 19, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Dec 15, 2025 | Dec 15, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 4, 2025 | Dec 4, 2025 |
| DEFA14A | Additional proxy material | Nov 14, 2025 | — |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2025 | Nov 14, 2025 |
| DEFA14A | Additional proxy material | Nov 13, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Nov 13, 2025 | Nov 12, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 14, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2025 | Sep 8, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jul 9, 2025 | — |
| 424B5 | Prospectus supplement | Jun 16, 2025 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2025 | Jun 13, 2025 |
| 10-Q/A | Amended quarterly report | Jun 11, 2025 | Mar 31, 2025 |
| 10-K/A | Amended annual report | Jun 11, 2025 | Dec 31, 2024 |
| DEFR14A | Filing | Jun 11, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 30, 2025 | — |
| 4 | Insider transaction | May 23, 2025 | May 21, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 21, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 21, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 21, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 21, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 21, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 21, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 21, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 21, 2025 |
| 4 | Insider transaction | May 21, 2025 | May 19, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
May 20, 2025 | May 20, 2025 |
| 4 | Insider transaction | May 16, 2025 | May 14, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| S-8 | Employee stock plan registration | May 14, 2025 | — |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| 4 | Insider transaction | May 1, 2025 | Apr 29, 2025 |
| 3 | Initial insider ownership | May 1, 2025 | Apr 29, 2025 |
| ARS | Annual report to shareholders | Apr 29, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Apr 29, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Listing notice
|
Apr 25, 2025 | Apr 22, 2025 |
| 8-K |
Current report
Officer or director change
|
Apr 21, 2025 | Apr 19, 2025 |
| 8-K |
Current report
Officer or director change
|
Apr 8, 2025 | Apr 3, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 27, 2025 | Mar 24, 2025 |
| 10-K | Annual report | Mar 24, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 24, 2025 | Mar 24, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 10, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 10, 2025 | Mar 10, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 7, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 3, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 28, 2025 | — |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure
|
Feb 24, 2025 | Feb 24, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| 8-K |
Current report
Listing notice
|
Feb 7, 2025 | Feb 3, 2025 |
| DEF 14A | Proxy statement | Jan 23, 2025 | Feb 24, 2025 |
| SCHEDULE 13D | Ownership over 5% (active) | Jan 22, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 13, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 13, 2025 | — |
| PRE 14A | Preliminary proxy statement | Jan 13, 2025 | Feb 24, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 8, 2025 | — |
| 8-K |
Current report
Material agreement, Other events
|
Jan 7, 2025 | Jan 6, 2025 |
| 424B5 | Prospectus supplement | Jan 7, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 6, 2025 | Jan 6, 2025 |
| 424B5 | Prospectus supplement | Jan 6, 2025 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Dec 20, 2024 | Dec 18, 2024 |
| SC 13G | Ownership over 5% (passive) | Nov 14, 2024 | — |
| 424B3 | Prospectus | Nov 13, 2024 | — |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 7, 2024 | Oct 7, 2024 |
| 4/A | Ownership document | Sep 10, 2024 | Aug 31, 2024 |
| 4 | Insider transaction | Sep 4, 2024 | Aug 31, 2024 |
| 4 | Insider transaction | Sep 4, 2024 | Aug 31, 2024 |
| 4 | Insider transaction | Sep 4, 2024 | Aug 31, 2024 |
| 4 | Insider transaction | Sep 4, 2024 | Aug 31, 2024 |
| 4 | Insider transaction | Sep 4, 2024 | Aug 31, 2024 |
| 4 | Insider transaction | Sep 4, 2024 | Aug 31, 2024 |
| 4 | Insider transaction | Sep 4, 2024 | Aug 31, 2024 |
| 4 | Insider transaction | Sep 4, 2024 | Aug 31, 2024 |
| EFFECT | Filing | Aug 21, 2024 | — |
| 424B5 | Prospectus supplement | Aug 21, 2024 | — |
| CORRESP | Letter to the SEC | Aug 20, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 19, 2024 | — |
| S-3 | Shelf registration | Aug 15, 2024 | — |
| 424B3 | Prospectus | Aug 12, 2024 | — |
| 10-K/A | Amended annual report | Aug 12, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2024 | Aug 12, 2024 |
| 10-Q | Quarterly report | Aug 12, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 6, 2024 | Aug 6, 2024 |
| EFFECT | Filing | Aug 5, 2024 | — |
| 424B3 | Prospectus | Aug 5, 2024 | — |
| CORRESP | Letter to the SEC | Aug 2, 2024 | — |
| 144 | Notice of proposed sale | Jul 29, 2024 | — |
| CORRESP | Letter to the SEC | Jul 23, 2024 | — |
| S-1/A | Amended registration statement | Jul 23, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2024 | — |
| 8-K |
Current report
Other events
|
Jul 9, 2024 | Jul 9, 2024 |
| CORRESP | Letter to the SEC | Jul 9, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 28, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 27, 2024 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2024 | Jun 14, 2024 |
| CORRESP | Letter to the SEC | May 31, 2024 | — |
| S-1/A | Amended registration statement | May 31, 2024 | — |
| 3 | Initial insider ownership | May 24, 2024 | May 17, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
May 16, 2024 | May 16, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| ARS/A | Filing | May 14, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | May 14, 2024 | — |
| 10-K/A | Amended annual report | May 14, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Restatement
|
May 3, 2024 | May 1, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 3, 2024 | May 3, 2024 |
| UPLOAD | Letter from the SEC | Apr 30, 2024 | — |
| ARS | Annual report to shareholders | Apr 29, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 14, 2024 |
| 25-NSE | Delisting notice | Apr 29, 2024 | — |
| 3 | Initial insider ownership | Apr 18, 2024 | Apr 12, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2024 | Jun 14, 2024 |
| 8-K |
Current report
Material agreement, New debt, Officer or director change
|
Apr 17, 2024 | Apr 12, 2024 |
| 4/A | Filing | Apr 16, 2024 | Apr 12, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 15, 2024 | Apr 15, 2024 |
| 4 | Insider transaction | Apr 12, 2024 | Apr 11, 2024 |
| CORRESP | Letter to the SEC | Apr 2, 2024 | — |
| S-1/A | Amended registration statement | Apr 2, 2024 | — |
| S-8 | Employee stock plan registration | Apr 1, 2024 | — |
| 8-K |
Current report
Other events
|
Mar 29, 2024 | Mar 29, 2024 |
| 10-K | Annual report | Mar 29, 2024 | Dec 31, 2023 |
| 10-Q/A | Amended quarterly report | Mar 29, 2024 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 29, 2024 | Mar 29, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 28, 2024 | Mar 24, 2024 |
| 4 | Insider transaction | Mar 26, 2024 | Mar 24, 2024 |
| 4 | Insider transaction | Mar 21, 2024 | Mar 19, 2024 |
| 4 | Insider transaction | Mar 21, 2024 | Mar 19, 2024 |
| 4 | Insider transaction | Mar 21, 2024 | Mar 19, 2024 |
| 4 | Insider transaction | Mar 21, 2024 | Mar 19, 2024 |
| 4 | Insider transaction | Mar 21, 2024 | Mar 19, 2024 |
| 4 | Insider transaction | Mar 21, 2024 | Mar 19, 2024 |
| 4 | Insider transaction | Mar 21, 2024 | Mar 19, 2024 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt, Unregistered share sale, Regulation FD disclosure
|
Mar 19, 2024 | Mar 18, 2024 |
| CORRESP | Letter to the SEC | Feb 27, 2024 | — |
| 8-K |
Current report
Restatement
|
Feb 16, 2024 | Feb 14, 2024 |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AEON (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Aliso Viejo, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1837607
- Former names
- Priveterra Acquisition Corp. (until Jul 24, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.